Aarey Drugs & Pharmaceuticals Ltd

BSE: AAREYDRUGS524412ISIN INE198H01019

Healthcare
Pharmaceuticals

Share price

₹108.65+3.05 (+2.89%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹118.90
52W low: ₹50.40
Off 52W high: -8.62%
1M return: +5.23%
3M return: +29.44%
6M return: +21.51%
1Y return: +10.69%
20D avg volume: 8,640
50 DMA: ₹100.60
200 DMA: ₹82.86

Key ratios Standalone

Market cap: ₹308.07 Cr
Current price: ₹108.65
52W high / low: ₹118.90 / ₹50.40
Face value: ₹10.00
P/E: 71.01
P/B: 2.55
EPS (TTM): ₹1.53
Book value / share: ₹42.61
ROE: 3.60%
ROCE: 6.80%
Operating margin: 6.81%
Net margin: 2.29%
Debt / equity: 0.33
Net debt: ₹48.56 Cr
Interest cover: 2.08
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 69.2 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	44.63	189.47	96.43	84.16	102.21	108.10	133.79	105.14	126.91	210.35	76.48	57.83
	1.72	0.43	4.18	0.79	1.55	7.54	0.68	0.02	1.57	5.14	0.29	0.83
	46.34	189.04	100.61	84.95	103.76	115.64	134.47	105.16	128.49	215.49	76.77	58.67
	45.83	187.76	99.69	83.47	102.03	114.01	133.07	103.42	127.16	213.35	75.31	57.66
	43.48	179.30	99.30	78.89	93.07	123.75	131.46	102.56	115.09	213.81	77.22	53.36
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	0.16	0.29	0.15	0.19	0.14	0.27	0.18	0.22	0.14	0.30	0.20	0.09
	1.67	1.78	0.92	1.26	1.04	3.13	0.90	1.51	0.96	1.15	1.06	1.27
	0.85	0.85	0.83	0.69	0.49	-1.42	0.58	0.49	0.47	0.40	0.47	0.41
	0.98	5.45	1.00	0.85	2.53	2.86	0.76	—	—	—	0.64	0.41
	0.52	1.28	0.92	1.48	1.73	1.62	1.40	1.75	1.33	2.15	1.47	1.01
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	0.52	1.28	0.92	1.48	1.73	1.62	1.40	1.75	1.33	2.15	1.47	1.01
	-0.51	-0.28	0.35	0.46	0.36	1.16	0.68	0.15	0.09	0.01	0.44	0.22
	1.02	1.56	1.28	1.02	1.37	0.47	0.72	1.60	1.24	2.15	1.02	0.79
	0.36	0.55	0.20	0.72	0.48	0.17	0.26	0.57	0.44	0.77	0.40	0.31
Key metrics
	3.04	3.91	2.67	3.43	3.26	3.33	2.88	3.75	2.76	3.70	3.00	2.69
	6.80%	2.10%	2.80%	4.10%	3.20%	3.10%	2.20%	3.60%	2.20%	1.80%	3.90%	4.70%
	2.30%	0.80%	1.30%	1.20%	1.30%	0.40%	0.50%	1.50%	1.00%	1.00%	1.30%	1.40%
	—	2.00%	—	1.80%	—	3.40%	—	—	—	—	—	—
	-56.30%	75.30%	-27.90%	-20.00%	-19.50%	-48.60%	74.90%	81.80%	—	—	—	—
	-25.50%	231.90%	77.80%	-36.30%	10.50%	-78.10%	-29.40%	102.50%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	414.69	472.27	473.94	395.62	62.47	492.68
	7.12	6.10	9.81	6.96	0.48	2.75
	420.94	478.37	483.76	402.58	62.95	495.43
	416.75	472.95	477.65	397.24	62.20	485.40
	400.97	450.56	472.87	387.76	60.07	—
	0.00	0.00	0.00	—	—	—
	0.79	0.76	0.81	0.72	0.18	4.78
	5.63	5.00	4.66	4.38	0.55	2.00
	3.22	2.85	1.94	1.70	0.71	1.99
	8.28	9.83	8.18	—	1.83	8.37
	4.20	5.41	6.10	5.34	0.75	10.03
	0.00	0.00	0.00	—	—	—
	4.20	5.41	6.10	5.34	0.75	10.03
	0.02	1.45	2.08	0.66	0.25	3.48
	4.88	3.97	4.02	4.68	0.49	6.54
	1.83	1.39	1.42	1.84	0.19	2.72
Key metrics
	13.05	13.26	12.70	11.42	2.01	14.02
	3.15%	2.80%	2.70%	2.90%	3.20%	2.80%
	1.18%	0.80%	0.80%	1.20%	0.80%	1.30%
	—	6.80%	7.60%	—	—	—
	-7.69%	-0.40%	19.80%	533.30%	-87.30%	—
	17.31%	-1.20%	-14.10%	855.10%	-92.50%	—
	—	-2.27	5.10	—	—	—
	—	2.55	2.56	—	—	—
	—	0.33	0.25	—	—	—
	—	48.56	33.39	—	—	—
	—	69.2	58.8	—	—	—
Balance sheet
	—	297.25	290.59	—	—	—
	—	262.94	265.61	—	—	—
	—	1.40	1.47	—	—	—
	—	129.65	133.46	—	—	—
	—	41.54	45.48	—	—	—
	—	—	53.88	—	—	—
	—	25.78	16.22	—	—	—
	—	81.59	102.54	—	—	—
	—	145.08	149.21	—	—	—
	—	49.96	34.86	—	—	—
	—	48.99	32.87	—	—	—
	—	0.97	1.99	—	—	—
	—	150.42	138.48	—	—	—
Cash flow
	—	10.14	10.30	—	—	—
	—	-12.41	-5.94	—	—	—
	—	2.20	-4.48	—	—	—
	—	12.41	5.20	—	—	—

Compounded growth

Sales CAGR 3Y: +96.26%
Sales CAGR 5Y: —
Profit CAGR 3Y: +100.85%
Profit CAGR 5Y: —
Sales YoY (TTM): -7.69%
Profit YoY (TTM): +17.31%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 41.46%

Quarter	September 2026	June 2026
Promoter %	41.46%	42.78%

Holder	Type	Holding	Previous	Change
Bina Rajesh Ghatalia	Promoter	14.13%	14.59%	-0.46%
Mihir Rajesh Ghatalia	Promoter	9.98%	10.30%	-0.32%
Nimit Impex	Promoter Group	6.31%	6.51%	-0.20%
Nimit Rajesh Ghatalia	Promoter	5.18%	5.34%	-0.16%
Mira Mihir Ghatalia	Promoter	2.95%	3.04%	-0.09%
Elysian Wealth Fund	Public	2.78%	2.87%	-0.09%
Ekta Nimit Ghatalia	Promoter	1.57%	1.62%	-0.05%
Krishnamurthy C G	Public	1.57%	1.62%	-0.05%
Suvi Rubber Pvt Ltd	Public	1.47%	1.52%	-0.05%
Shree Salasar Properties And Finance Private Limited	Public	1.44%	1.49%	-0.05%
Chetan Kirtibhai Mehta	Public	1.25%	1.30%	-0.05%
Richa Bothra	Public	1.21%	1.25%	-0.04%
MIHIR RAJESH GHATALIA HUF	Promoter	0.77%	0.79%	-0.02%
Rajesh Pranlal Ghatalia	Promoter	0.57%	0.59%	-0.02%
Worth Investment and Trading Company Limited	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Aarey Drugs & Pharmaceuticals Ltd S	308	108.65	71.01	6.80%	-7.69% TTM	+17.31% TTM	+10.69%

Filings & corporate actions

Recent announcements

Compliance Certificate Under Reg 74(5) of SEBI(DP) Regulation 20188 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Revised outcome7 Oct 2026 · Company Update / Revision of outcome
Scrutinizers Report of 36th Annual General Meeting5 Oct 2026 · AGM/EGM / AGM
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nimit Rajesh Ghatalia5 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nimit Rajesh Ghatalia5 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
DISCLOSURE AS PER SEBI SAST REG 29(1) REG 20113 Oct 2026 · Others
DISCLOSURE UNDER SEBI SAST REG 29(2) REG 20113 Oct 2026 · Others
Disclosure under SEBI PIT Reg. 20153 Oct 2026 · Others
AGM Proceedings of 36th Annual General Meeting30 Sep 2026 · AGM/EGM / AGM
Revised Outcome of Board Meeting dated 06-08-2026 approved in Board Meeting 30-09-202630 Sep 2026 · Company Update / General
OUTCOME OF BOARD MEETING HELD ON 30-09-202630 Sep 2026 · Others / Outcome without intimation
Intimation for Closure of trading Window23 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Disclosure Under Regulation 30of SEBI(Listing Obligation And Disclosure Requirement ) Regulation, 201511 Sep 2026 · Company Update / General
Newspaper Publication9 Sep 2026 · Company Update / Newspaper Publication
Notice and Integrated Annual Report for 36TH Annual General Meeting of Company as required under Regulation 34(1)8 Sep 2026 · Others / Reg. 34 (1) Annual Report
Notice of 36th Annual General Meeting of the Company for the FY 2025-268 Sep 2026 · AGM/EGM / AGM
Intimation of Book Closure8 Sep 2026 · Corp. Action / Book Closure
As per attachment5 Sep 2026 · Others / Outcome without intimation
As per the attachment17 Aug 2026 · Company Update / Newspaper Publication
As per Attachment14 Aug 2026 · Result / Financial Results
Outcome of Board Meeting held on friday, 14th August, 202614 Aug 2026 · Board Meeting / Outcome of Board Meeting
Aarey Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve This is to intimate ....7 Aug 2026 · Board Meeting / Board Meeting
Allotment of Equity Shares Pursuant to Conversion of Warrants6 Aug 2026 · Others / Outcome without intimation
Compliance Certificate under Reg 74(5) of Sebi(DP) Regulation 20188 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation for closure of trading window26 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
As per Attachment2 Jun 2026 · Company Update / Newspaper Publication
As per attachment30 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
as per attachment30 May 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
As per Attachment30 May 2026 · Result / Financial Results
Outcome of Board Meeting held on Saturday, 30th May, 202630 May 2026 · Board Meeting / Outcome of Board Meeting
Aarey Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve intimation regarding ....29 May 2026 · Company Update / Board Meeting Rescheduled
Aarey Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Pursuant to the ....25 May 2026 · Board Meeting / Board Meeting
Certificate under Reg 74(5) of SEBI (Depositories and Participants) Regulations, 201814 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation for closure of trading window26 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
Newspaper Publication of the Unaudited Financial Results14 Feb 2026 · Company Update / Newspaper Publication
Board Comments on the fine levied by the Exchange12 Feb 2026 · Company Update / General
Approval of Unaudited Financial Results for the quarter ended 31st December, 202511 Feb 2026 · Result / Financial Results
This is to inform you that the Board of Directors of the Company at its Meeting held today i.e. 11th February, 2026 have passed the following resolution. 1. The Board of Directors of the ....11 Feb 2026 · Board Meeting / Outcome of Board Meeting
Aarey Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 ,inter alia, to consider and approve This is to intimate ....4 Feb 2026 · Board Meeting / Board Meeting
Certificate under reg 74(5) of SEBI (Depositories and Participants) Regulations, 201814 Jan 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Board meetings

14 Aug 2026 Board Meeting - Financial Results